135 related articles for article (PubMed ID: 19922075)
1. A short-term model for preliminary screening of potential anti-tubercular compounds.
Jhamb SS; Singh PP
Scand J Infect Dis; 2009; 41(11-12):886-9. PubMed ID: 19922075
[TBL] [Abstract][Full Text] [Related]
2. A comparison of conventional and radiometric methods for the assessment of anti-tubercular activity of drugs against Mycobacterium tuberculosis in mice and macrophage models.
Jhamb SS; Singh RP; Singh PP
Indian J Tuberc; 2008 Apr; 55(2):70-6. PubMed ID: 18516822
[TBL] [Abstract][Full Text] [Related]
3. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis.
Taneja NK; Tyagi JS
J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
Lu T; Drlica K
J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
[TBL] [Abstract][Full Text] [Related]
5. [Establishment and drug susceptibility test of isoniazid resistant Mycobacterium smegmatis].
Jia PP; Zhao LL; Li XY; Zhang Q; Liu ZL; Wang X; Yu LY; Zhao LX; Cen S
Yao Xue Xue Bao; 2011 Apr; 46(4):377-82. PubMed ID: 21751489
[TBL] [Abstract][Full Text] [Related]
6. Antimycobacterial activities of novel fluoroquinolones.
Senthilkumar P; Dinakaran M; Yogeeswari P; China A; Nagaraja V; Sriram D
Biomed Pharmacother; 2009 Jan; 63(1):27-35. PubMed ID: 18031974
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.
Altaf M; Miller CH; Bellows DS; O'Toole R
Tuberculosis (Edinb); 2010 Nov; 90(6):333-7. PubMed ID: 20933470
[TBL] [Abstract][Full Text] [Related]
8. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
10. Bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide on Mycobacterium tuberculosis in vitro.
Paramasivan CN; Herbert D; Prabhakar R
Indian J Med Res; 1993 Jul; 97():145-50. PubMed ID: 8406638
[TBL] [Abstract][Full Text] [Related]
11. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
Nikonenko BV; Samala R; Einck L; Nacy CA
Antimicrob Agents Chemother; 2004 Dec; 48(12):4550-5. PubMed ID: 15561824
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
13. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mycobacterial growth by plumbagin derivatives.
Mathew R; Kruthiventi AK; Prasad JV; Kumar SP; Srinu G; Chatterji D
Chem Biol Drug Des; 2010 Jul; 76(1):34-42. PubMed ID: 20456370
[TBL] [Abstract][Full Text] [Related]
15. Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection.
Rodrigues-Junior VS; Dos Santos Junior A; Dos Santos AJ; Schneider CZ; Calixto JB; Sousa EH; de França Lopes LG; Souto AA; Basso LA; Santos DS; Campos MM
Int J Antimicrob Agents; 2012 Aug; 40(2):182-5. PubMed ID: 22748570
[TBL] [Abstract][Full Text] [Related]
16. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria.
Kaur D; Khuller GK
Int J Antimicrob Agents; 2001 Jan; 17(1):51-5. PubMed ID: 11137649
[TBL] [Abstract][Full Text] [Related]
17. Anti-Mycobacterium activity of microbial peptides in a silkworm infection model with Mycobacterium smegmatis.
Yagi A; Uchida R; Hamamoto H; Sekimizu K; Kimura KI; Tomoda H
J Antibiot (Tokyo); 2017 May; 70(5):685-690. PubMed ID: 28446822
[TBL] [Abstract][Full Text] [Related]
18. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
Christophe T; Ewann F; Jeon HK; Cechetto J; Brodin P
Future Med Chem; 2010 Aug; 2(8):1283-93. PubMed ID: 21426019
[TBL] [Abstract][Full Text] [Related]
19. Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid.
Dinakaran M; Senthilkumar P; Yogeeswari P; China A; Nagaraja V; Sriram D
Bioorg Med Chem; 2008 Mar; 16(6):3408-18. PubMed ID: 18304818
[TBL] [Abstract][Full Text] [Related]
20. Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection.
Shoen CM; DeStefano MS; Cynamon MH
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S288-90. PubMed ID: 10875802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
